TICKERNERD
Menu
IGCIGCHealthcare · Biotechnology

IGC Stock Forecast: IGC Pharma, Inc. Price Predictions for 2026-2027

Last close, 7 Oct 2026
$0.28
0.00% on the day

The 1 Wall Street analysts covering IGC Pharma, Inc. hold a median 12-month price target of $6 — +2042.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 6 of 100 as at 6 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$28.9M
Ticker Nerd rank
6 / 100
Median analyst target
$6.00
Analysts covering
1
Revenue$317K−3.9% y/y
Operating income−$2.5M
Net income−$2.4M
Free cash flow−$1.4M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.7%
1M
−6.7%
YTD
0.0%
1Y
−31.7%
From 52W high
−33.3%
From 52W low
+16.7%
$0.24
$0.42
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IGC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores IGC Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Oct 2026
6 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Volatility
68
Revisions
53
Accruals
12
Momentum
9
Value
8
Issuance
8
Growth
1
Quality
1

Size (86): Smaller than most of the companies we track.

Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IGC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IGC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00$6.00Jan 26Apr 26Jul 26Oct 26IGCHigh $6.00Median $6.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $6.00Median $6.00High $6.00

The green dot is the last close — the median target sits +2042.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Aug 2026Ascendiant CapitalMaintainsBuy—
8 June 2026Ascendiant CapitalMaintainsBuy—
8 Apr 2026Ascendiant CapitalMaintainsBuy—
23 Feb 2026Ascendiant CapitalMaintainsBuy—
9 Dec 2025Ascendiant CapitalMaintainsBuy—
26 Aug 2025Ascendiant CapitalMaintainsBuy—
6 Mar 2025Alliance Global PartnersReiteratesBuy—
24 Feb 2025Ascendiant CapitalMaintainsBuy—
5 Dec 2024Ascendiant CapitalMaintainsBuy—
3 Sept 2024Ascendiant CapitalMaintainsBuy—
29 July 2024Ascendiant CapitalMaintainsBuy—
17 July 2024Alliance Global PartnersInitiatesBuy—
21 June 2024Ascendiant CapitalReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IGC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IGC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, IGC Pharma, Inc. returned −31.7% against +17.4% for the S&P 500, dividends included.

IGC vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26IGCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IGC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

IGC Pharma, Inc. (IGC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 88% of US stocks

Price / sales
26.7×

Cheaper than 8% of US stocks

Price / book
4.8×

Cheaper than 22% of US stocks

EV / EBITDA
−3.9×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
−19.2%

Higher than 12% of US stocks

Earnings growth (YoY)
−3.9%

Higher than 32% of US stocks

Gross margin
17.4%

Higher than 17% of US stocks

Operating margin
−1050.6%

Higher than 5% of US stocks

Net margin
48.7%

Higher than 96% of US stocks

Returns & dividend
Return on equity
−83.3%

Higher than 15% of US stocks

Return on assets
−50.3%

Higher than 8% of US stocks

Dividend yield
28.1%

Higher than 98% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

IGC Pharma, Inc. (IGC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IGC Pharma, Inc. has a market value of $28.9M and an enterprise value of $29.7M.

  • Revenue in the twelve months to 31 Mar 2026: $1.2M. The latest quarter shrank 19.2% year on year.

  • Net income over the same four quarters: −$6.5M, a −552.1% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$6.8M, after $631K of capital spending.

  • Shares outstanding: 103.4M.

  • Trailing P/E: −3.2×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 28.09%, paying out 0% of earnings.

  • IGC Pharma, Inc. employs 70 people — $17K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

IGC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IGCIGC Pharma, Inc.$28.9M
6
BYSIBeyondSpring, Inc.$28.5M
19
GRDXGridAI Technologies Corp.$29.5M
19
CNTXContext Therapeutics, Inc.$29.6M
26
RNAZTransCode Therapeutics, Inc.$30.1M
21
MCRBSeres Therapeutics, Inc.$27.8M
56
ATYRaTyr Pharma, Inc.$27.8M
53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own IGC Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IGC news & analysis

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

Accesswire · 28 Sept 2026positive

IGC Pharma announced it has completed enrollment in its CALMA Phase 2 trial of lead asset IGC-AD1 for agitation in Alzheimer's dementia, with 168 participants randomized. Final dosing is expected to conclude in early November, with topline results anticipated in Q4 2026.

Why it matters — Completion of enrollment moves the lead Alzheimer's candidate forward and sets a clear timeline for topline results, a key milestone for IGC watchers tracking the trial's progress.

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

Accesswire · 17 Aug 2026positive

IGC Pharma reported its Q2 2026 financial results and provided an update on its lead Alzheimer's program, IGC-AD1. The Phase 2 CALMA trial reached the previously disclosed 146-patient baseline randomization target, with a topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding.

Why it matters — Reaching the CALMA trial's baseline randomization target moves IGC's lead Alzheimer's candidate closer to a Phase 2 data readout expected in the fourth quarter of 2026.

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

Accesswire · 11 Aug 2026positive

IGC Pharma announced it is strengthening its regulatory, biostatistical, AI-enabled data science, and pharmaceutical development capabilities as its lead Alzheimer's drug candidate IGC-AD1 nears expected Phase 2 topline results in Q4 2026. The CALMA trial has randomized 160 participants to date and is approaching enrollment closure.

Why it matters — Investors are watching IGC's progress toward Phase 2 topline results for IGC-AD1, the company's lead Alzheimer's candidate, with enrollment closure approaching and regulatory readiness being enhanced ahead of the expected Q4 2026 data readout.

IGC Pharma Evaluates Potential Recovery Options as Federal Jury Verdict Brings Renewed Attention to 2018 IGC Short Campaign

Accesswire · 29 July 2026positive

IGC Pharma announced it is evaluating potential civil remedies after a federal jury verdict in United States v. Andrew Left brought renewed attention to a 2018 short campaign against the company.

Why it matters — The verdict could lead to recovery options for IGC related to the 2018 short campaign, which may have financial implications for the company.

FAQ

Frequently asked questions about IGC stock

What is the IGC stock price forecast for 2026-2027?

The 1 Wall Street analysts covering IGC Pharma, Inc. have a median 12-month price target of $6, with estimates ranging from $6 to $6. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IGC stock a buy right now?

Of the 1 analysts covering IGC Pharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IGC Pharma, Inc. 6 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IGC?

As at 6 Oct 2026, IGC Pharma, Inc. ranks 6 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

Will IGC stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +2042.9% from the last close, and Ticker Nerd's factor model ranks IGC Pharma, Inc. 6 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IGC stock forecast for 2030?

No analyst covering IGC Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IGC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $6 over the next 12 months.

How has IGC stock performed over the past year?

IGC Pharma, Inc. returned -31.7% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does IGC Pharma, Inc. do?

IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies for Alzheimer’s disease and related neurodegenerative conditions.

What is the latest news on IGC?

The most recent item we track (Accesswire, 28 Sept 2026): "IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026". IGC Pharma announced it has completed enrollment in its CALMA Phase 2 trial of lead asset IGC-AD1 for agitation in Alzheimer's dementia, with 168 participants randomized. Final dosing is expected to conclude in early November, with topline results anticipated in Q4 2026.

Company

About IGC Pharma, Inc.

IGC Pharma, Inc. is a clinical-stage biotechnology company focused on developing therapies for Alzheimer’s disease and related neurodegenerative conditions. Its current pipeline centers on IGC-AD1, a cannabinoid-based investigational treatment for agitation in dementia associated with Alzheimer’s disease, alongside preclinical programs such as TGR-63 and other compounds targeting Alzheimer’s-related pathology and metabolic dysfunction. The company also develops AI-enabled tools, including MINT-AD and related healthcare applications, to support risk assessment, research, and clinical decision-making in cognitive disorders. IGC Pharma operates in the pharmaceutical and biotechnology sectors, with activities spanning drug discovery, clinical research, and the development of cannabinoid-based formulations for neurological and metabolic indications. Headquartered in Potomac, Maryland, the company serves the broader life sciences market through its focus on innovative treatments and technology-driven support tools for patients, caregivers, and healthcare providers.

CEO Mr. Ram Mukunda · 70 employees · United States · https://igcpharma.com